Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company, specializes in the emerging field of molecular medicine. The company is committed to applying innovations in the identification and targeting of disease to enhance patient healthcare by treating significant, but unmet medical needs. Their focus is on discovering, developing and commercializing novel radiotherapeutics and molecular imaging pharmaceuticals for initial application in the areas of oncology and cardiology. For further information, visit the Company’s web site at www.molecularinsight.com.
- 17 years ago
QualityStocks
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Onar Holding Corporation (OTCQB: ONAR) Details Board Additions, AI Partnerships and M&A Moves
Onar (OTCQB: ONAR), a marketing technology company and global network of performance-driven agencies, issued a…
-
QualityStocksNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Sees 504% Boat Sales Surge, Slashes Debt Following Nautical Ventures Acquisition
Vision Marine Technologies (NASDAQ: VMAR), a leader in electric marine propulsion and multi-brand boat…
-
Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures $18.4M DoD Award to Fast-Track Heavy Rare Earth Independence
This phase 2 award builds on phase 1 success, during which Ucore successfully separated two heavy…